PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC

High expression of PD-L1 marks the poor prognosis of pancreatic ductal adenocarcinomas (PDAC). However, the regulatory mechanism of PD-L1 remains elusive. We recently reported that cancer Forkhead box protein 3 (Cancer-FOXP3 or C-FOXP3) promoted immune evasion of PDAC by recruiting Treg cells into P...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiuchao, Li, Xin, Wei, Xunbin, Jiang, Haiping, Lan, Chungen, Yang, Shengyu, Wang, Han, Yang, Yanhui, Tian, Caijuan, Xu, Zanmei, Zhang, Jiangyan, Hao, Jihui, Ren, He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162990/
https://www.ncbi.nlm.nih.gov/pubmed/32300119
http://dx.doi.org/10.1038/s41392-020-0144-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162990/
https://www.ncbi.nlm.nih.gov/pubmed/32300119
http://dx.doi.org/10.1038/s41392-020-0144-8

Ejemplares similares